• Celgene, Acceleron to file MDS therapy in the EU, US pharmatimes
    July 04, 2018
    Celgene and Acceleron Pharma are preparing to file their experimental myelodysplastic syndromes (MDS) therapy on both sides of the Atlantic on the back of promising data from a late-stage study.
PharmaSources Customer Service